1Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Manitoba, Canada

2Max Rady Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

3Population Health Research Institute, Hamilton Health Sciences/McMaster University, Hamilton, Ontario, Canada

4Department of Medicine, Division of Nephrology, University of Alberta, Edmonton, Alberta, Canada

5Department of Medicine, Division of Nephrology, University of Calgary, Calgary, Alberta, Canada

Correspondence: Dr. David Collister, Department of Medicine, Division of Nephrology, University of Alberta, 11-112R Clinical Sciences Building, 11350 83 Avenue, Edmonton, Alberta T6G 2P4, Canada. Email: [email protected]

See related article, “Cystatin C–Based eGFR Changes during Gender-Affirming Hormone Therapy in Transgender Individuals,” on pages 1545–1554.